STXS

Stereotaxis, Inc. 2004 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2004. Stereotaxis, Inc. designs, manufactures, and markets the Stereotaxis System, an advanced cardiology instrument control system that uses magnetic fields to remotely navigate catheters and guidewires in the heart. The company emerged from a development stage in 2003 and completed its Initial Public Offering (IPO) in August 2004. As of year-end, the company had sold and delivered 30 systems (20 in the U.S., 10 internationally) and had purchase orders for an additional $20 million.

Key Financial Metrics

Revenue Breakdown (2004): Systems revenue was $17.2 million; disposables, service, and accessories revenue was $1.6 million.

Expense Breakdown (2004): Research and Development (R&D) was $18.4 million; Sales and Marketing was $11.0 million; General and Administrative (G&A) was $6.3 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 275% year-over-year, driven by a 352% increase in system sales (22 systems sold in 2004 vs. 8 in 2003) and a 232% increase in recurring revenue from disposables and services.
• Margin Expansion: Gross margin improved significantly from 19.2% to 43.3% due to a 17% reduction in average cost per system and an increase in average selling price.
• Liquidity Position: Cash and short-term investments increased by $19.2 million to $45.6 million, primarily due to net proceeds of approximately $41.4 million from the August 2004 IPO.
• Debt Reduction: Long-term debt decreased as a $2.0 million convertible note to Siemens was converted to common stock upon the IPO.
• Expense Increases: R&D expenses rose 33% due to expanded projects with strategic partners and additional personnel. Sales and marketing expenses rose 83% to support commercialization.

Guidance, Outlook, and Risks

Outlook: Management expects to incur additional losses through the first half of 2006 as the company continues product development, commercialization, and R&D. The company anticipates negative cash flow from operations for the foreseeable future.

Strategic Partnerships: The company relies heavily on alliances with Siemens, Philips, and Johnson & Johnson (J&J) for system integration, sales, and service. Siemens and Philips provide worldwide service for integrated systems.

Key Risks and Contingencies:

• Profitability: The company has an accumulated deficit of $114.7 million and may never achieve profitable operations.
• Market Adoption: Success depends on hospitals purchasing expensive capital equipment and physicians adopting a new technology over established manual methods.
• Regulatory: Future growth depends on obtaining FDA clearance for new disposable devices (e.g., HELIOS ablation catheter PMA filing expected) and maintaining existing clearances.
• Supply Chain: The company relies on single suppliers for critical components, including magnets sourced from Japan.
• Reimbursement: While current procedures are generally reimbursed, future changes in third-party payor policies could impact demand.

Investor Verification Checklist

• Order Book Realization: Verify the conversion rate of the $20 million in purchase orders and commitments into recognized revenue, noting that orders are subject to contingencies and cancellations.
• Recurring Revenue Trajectory: Monitor the growth of disposables and service revenue relative to the installed base of 30 systems to validate the recurring revenue model.
• Regulatory Milestones: Track the status of the PMA filing for the HELIOS ablation catheter and other new disposable devices, as these are critical for expanding the product toolkit.
• Partnership Execution: Assess the progress of system integrations with Philips and J&J, and the volume of co-placed systems, as these partners are essential for distribution and service.
• Cash Burn Rate: Evaluate the sustainability of the $45.6 million cash position against the projected operating losses and capital requirements through 2006.